跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
RIVASTIGMINE-DRLA rivastigmine (as hydrogen tartrate) 3 mg capsule blister pack - TGA Drug Approval Details
Approvals
/
TGA
/
RIVASTIGMINE-DRLA rivastigmine (as hydrogen tartrate) 3 mg capsule blister pack
Approved
STANDARD
RIVASTIGMINE-DRLA rivastigmine (as hydrogen tartrate) 3 mg capsule blister pack
Dr Reddys Laboratories Australia Pty Ltd
🇦🇺 Therapeutic Goods Administration
Approval Date
May 29, 2025
Approval ID
2543e8f39129e32d
Company
Dr Reddys Laboratories Australia Pty Ltd
Type
Standard
Approval Details
Approval Id
2543e8f39129e32d
Product Name
RIVASTIGMINE-DRLA rivastigmine (as hydrogen tartrate) 3 mg capsule blister pack
Artg Id
177398
Artg Name
RIVASTIGMINE-DRLA rivastigmine (as hydrogen tartrate) 3 mg capsule blister pack
Sponsor
Dr Reddys Laboratories Australia Pty Ltd
Company Detail Path
/organization/dr-reddys-laboratories-australia-pty-ltd
Artg Date
2012-09-24
Registration Type
Medicine
Therapeutic Good Type
Medicine
Licence Status
A
Licence Category
RE
Active Ingredients
Approved
Quick Info
Agency
TGA
Country
🇦🇺
Approval Date
May 29, 2025
Approval ID
2543e8f39129e32d
Type
Standard
Back to TGA Approvals
